Dozens of people sue GLP-1 drug companies over alleged vision loss

More than 90 lawsuits have been filed against Novo Nordisk in New Jersey since 2025 alleging GLP-1 drugs caused NAION, a rare and potentially irreversible vision-loss condition; additional cases target GLP-1 makers in federal court. The potential litigation and safety risk challenge a GLP-1 market analysts expect could reach roughly $100 billion in annual sales within 10 years, although evidence on causality remains mixed. Novo Nordisk says its randomized-trial study found no increased NAION risk, while the EMA estimates the condition may affect about 1 in 10,000 GLP-1 users with diabetes and the FDA continues to investigate.

Analysis

The market impact is more likely to run through labeling, patient-screening friction and persistence than near-term damages. A causal finding or label change would raise prescriber documentation requirements and may deter marginal obesity patients, pressuring the long-duration penetration assumptions embedded in LLY and NVO multiples; the highest-risk cohort is likely diabetics with pre-existing vascular disease, where attribution is inherently confounded. NVO has greater headline sensitivity because the litigation is presently more concentrated there, but LLY is not insulated if FDA treats this as a class-effect signal.

Over the next 1-3 months, the key catalyst is not lawsuit count but whether FDA converts its review into a safety communication, label action, or request for post-marketing data. Company-sponsored randomized-trial analyses should not be treated as dispositive: NAION is rare enough that trial programs may be underpowered for a definitive exclusion, while observational signals can be distorted by diabetes severity and rapid metabolic change. Absence of regulatory action would likely make this a transient volatility event, especially if quarterly prescription growth and discontinuation rates remain intact.

A second-order beneficiary could be non-incretin obesity platforms, including VKTX and AMGN, only if safety concerns become specific to existing GLP-1 products rather than obesity pharmacotherapy broadly. That distinction matters: a class-wide vascular-risk warning would compress the entire obesity-drug opportunity set, whereas a molecule-, dose-, or patient-selection-specific finding could create a relative-safety premium for pipeline competitors. The contrarian view is that the current signal is insufficient to impair demand materially; however, the downside is asymmetric because regulatory language can alter adoption before legal causation is resolved.

Key Decisions for Investors

• Do not add directional short exposure to LLY or NVO solely on litigation headlines. Establish an FDA-monitoring trigger: a formal safety communication, label revision, or REMS-style patient-screening requirement would justify reassessing 6-12 month revenue estimates and reducing GLP-1 exposure.
• For existing NVO exposure, favor a 1-3 month hedge through NVO put spreads rather than outright stock sales; use a structure sized to protect against a regulatory headline gap while limiting premium loss if no action occurs. Thesis is falsified by continued prescription growth, stable persistence, and no FDA escalation through the next reporting cycle.
• Maintain LLY/NVO relative-value discipline: a widening NVO discount attributable only to legal headlines, without evidence of differential labeling or prescription deterioration, is a potential long NVO/short LLY mean-reversion setup. Avoid entry until relative prescription trends and reimbursement dynamics confirm that the discount is not fundamental.
• Place VKTX and AMGN on an alert list rather than initiating a sympathy long. Upgrade only if regulators or independent data identify risk differentiation by molecule or mechanism; a class-wide warning would invalidate the relative-safety thesis and likely pressure both names.